Ensign Peak Advisors
XFOR icon

Ensign Peak Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Ensign Peak Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-74,522
Closed -$529K – 1725
2025
Q1 		$529K Sell
74,522
-10,360
-12% -$143K ﹤0.01% 1534
2024
Q4 		$1.87M Hold
84,882
– – ﹤0.01% 968
2024
Q3 		$1.7M Hold
84,882
– – ﹤0.01% 1020
2024
Q2 		$1.48M Buy
84,882
+3,701
+5% +$121K ﹤0.01% 1043
2024
Q1 		$3.39M Buy
+81,181
New +$2.26M 0.01% 762
2022
Q2 		– Sell
-5,884
Closed -$309K – 2208
2022
Q1 		$309K Hold
5,884
– – ﹤0.01% 1740
2021
Q4 		$404K Buy
5,884
+4,931
+517% +$624K ﹤0.01% 1700
2021
Q3 		$151K Hold
953
– – ﹤0.01% 1774
2021
Q2 		$186K Hold
953
– – ﹤0.01% 1732
2021
Q1 		$246K Sell
953
-49
-5% -$12.9K ﹤0.01% 1708
2020
Q4 		$193K Sell
1,002
-337
-25% -$66.2K ﹤0.01% 1732
2020
Q3 		$272K Buy
1,339
+1,135
+556% +$272K ﹤0.01% 1639
2020
Q2 		$57K Hold
204
– – ﹤0.01% 1657
2020
Q1 		$61K Sell
204
-205
-50% -$58.2K ﹤0.01% 1598
2019
Q4 		$131K Buy
+409
New +$147K ﹤0.01% 1636

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ensign Peak Advisors's XFOR Position: Q2 2025 in Review

Ensign Peak Advisors sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 74,522 shares — an estimated $529K sold.

Ensign Peak Advisors first reported a position in XFOR in Q4 2019 and held it in 15 quarters. The position peaked at $3.39M in Q1 2024. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

  • Ensign Peak Advisors reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 74,522 X4 Pharmaceuticals shares in Q2 2025, an estimated $529K.
  • Ensign Peak Advisors first reported a position in X4 Pharmaceuticals in Q4 2019 and held it in 15 quarters.
  • Ensign Peak Advisors's X4 Pharmaceuticals position peaked at $3.39M in Q1 2024.
  • 51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on Ensign Peak Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.